March 23, 2026
As the global toxicology community gathers in San Diego for the Society of Toxicology (SOT) Annual Meeting, sponsors are once again looking for partners who can do more than deliver isolated services. They are looking for integrated solutions—partners who can help them move seamlessly from early discovery through translational research with confidence, speed, and scientific rigor.
This year, ODIN Bioscience will be on-site alongside the Envol Biomedical team, offering a uniquely aligned approach to supporting drug development programs from the earliest stages of biological material sourcing through advanced preclinical research.
A New Standard for High-Quality Biological Matrices
For many biotech and pharmaceutical companies, progress begins with access to the right biological materials. ODIN Bioscience has positioned itself as a specialized provider of high-quality primate-derived biological matrices, tissues, and primary cells supporting a wide range of applications including assay development, biomarker research, and translational bridging strategies.
This is particularly valuable for organizations:
- Developing or validating assays using primate-relevant systems
- Bridging between species to improve translational confidence
- Leveraging non-animal methods (NAMs) while still requiring biologically relevant materials
- Advancing biomarker strategies tied to complex physiological systems
ODIN enables these programs by delivering well-characterized, high-integrity materials that reflect real biological conditions—providing a critical foundation for accurate, reliable data generation.
From Materials to Meaningful Research
What makes ODIN especially compelling at SOT is not just what they provide—but what they enable next.
For sponsors working with primate-derived materials, the natural next step often involves in vivo or translational research, and this is where alignment with Envol Biomedical becomes particularly powerful. Envol offers access to one of North America’s largest, well-controlled nonhuman primate colonies, supported by deep expertise in GLP-compliant toxicology and pharmacology. Their capabilities extend further into advanced surgical and dosing procedures, as well as fully integrated study execution across pharmacology, pharmacokinetics, and toxicology, allowing sponsors to move forward with confidence at every stage.
Together, ODIN and Envol create a continuous pathway that begins with sample acquisition and assay development, extends into model validation and translational research, and ultimately supports IND-enabling studies and beyond. This approach is not rigid or linear; sponsors may engage ODIN first and expand into research, or begin with Envol and incorporate ODIN’s materials in parallel. Either way, the outcome is a more cohesive development process—one that delivers greater continuity, stronger data alignment, and fewer disconnects between discovery and development.
Designed for Today’s Biotech and Pharma Innovators
The combined ODIN–Envol approach is particularly relevant for emerging biotech companies building early-stage platforms, as well as mid-size pharmaceutical teams advancing complex biologics. It also supports organizations navigating increasing regulatory expectations around translational relevance, especially those working to integrate non-animal methods with biologically grounded validation strategies.
By aligning high-quality biological inputs with high-quality research execution, sponsors gain a more unified development experience that reduces risk while accelerating timelines.
Join ODIN Bioscience and Envol Biomedical at SOT
Throughout the Society of Toxicology (SOT) Annual Meeting, representatives from both ODIN Bioscience and Envol Biomedical will be available to connect with attendees, discuss ongoing programs, and explore how this integrated model can support your next milestone.
You’ll also have the opportunity to join a hosted reception, where teams from both organizations will be available for more in-depth conversations in a relaxed setting.
Whether you are exploring new assay strategies, evaluating translational models, planning IND-enabling studies, or simply looking for a more connected way to advance your program, this is an opportunity to engage with a team that understands how each piece of the process fits together.
Build a More Connected Development Strategy
Drug development is rarely limited by a single step—it is more often constrained by the gaps between them.
By bringing together ODIN’s expertise in biological materials and Envol’s capabilities in translational research, sponsors can close those gaps and move forward with greater clarity, consistency, and confidence.
If you’re attending SOT in San Diego, make time to connect with the ODIN and Envol teams—and see how a more integrated approach can help move your science further, faster.